{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:36:29Z","timestamp":1697186189058},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6460,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1093\/annonc\/mdf129","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T18:59:57Z","timestamp":1027709997000},"page":"755-759","source":"Crossref","is-referenced-by-count":3,"title":["A phase I study of oral uracil\u2013ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors"],"prefix":"10.1016","volume":"13","author":[{"given":"F.","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.T.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"von Pawel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Boehlke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf129_bb0010","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00255750","article-title":"Pharmacokinetics of ftorafur after intravenous and oral administration","volume":"10","author":"Anttila","year":"1983","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdf129_bb0015","first-page":"517","article-title":"Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients","volume":"7","author":"Damle","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdf129_bb0020","first-page":"675","article-title":"Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver","volume":"7","author":"Komatsu","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdf129_bb0025","first-page":"381","article-title":"Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy","volume":"6","author":"Koukourakis","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdf129_bb0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.bjc.6690719","article-title":"The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma","volume":"81","author":"Saito","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf129_bb0035","first-page":"1167","article-title":"Determination of 5-fluorouracil levels in tumors, blood, and other tissues","volume":"5","author":"Taguchi","year":"1978","journal-title":"Jpn J Cancer Chemother"},{"key":"10.1093\/annonc\/mdf129_bb0040","first-page":"209","article-title":"Effect of co-administration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetra-hydrofuryl)-5-fluorouracil","volume":"70","author":"Fujii","year":"1979","journal-title":"Gann"},{"key":"10.1093\/annonc\/mdf129_bb0045","first-page":"2085","article-title":"Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2\u2032-tetrahydrofuryl)-5-fluorouracil","volume":"4","author":"Ho","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdf129_bb0050","first-page":"966","article-title":"Phase I study of UFT (uracil plus futraful preparation)","volume":"7","author":"Taguchi","year":"1980","journal-title":"Jpn J Cancer Chemother"},{"key":"10.1093\/annonc\/mdf129_bb0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/00001813-199609000-00002","article-title":"Phase I trials of uracil\u2013tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities","volume":"7","author":"Pazdur","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdf129_bb0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s002800050432","article-title":"A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer","volume":"37","author":"Meropol","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Abstr 1015","key":"10.1093\/annonc\/mdf129_bb0065","first-page":"18","article-title":"Randomized comparative study of ORZEL (oral uracil\/tegafur [UFT] plus leucovorin [LV]) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer","volume":"264a","author":"Carmichael","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf129_bb0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00000421-200012000-00019","article-title":"Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study","volume":"23","author":"Martin","year":"2000","journal-title":"Am J Clin Oncol"},{"issue":"Abstr 1009","key":"10.1093\/annonc\/mdf129_bb0075","first-page":"18","article-title":"Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leukovorin (LV) in patients with metastatic colorectal cancer","volume":"263a","author":"Pazdur","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf129_bb0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<211::AID-CNCR4>3.0.CO;2-O","article-title":"Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group","volume":"78","author":"Feliu","year":"1996","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf129_bb0085","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/1097-0142(20001015)89:8<1706::AID-CNCR9>3.0.CO;2-I","article-title":"Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group","volume":"89","author":"Feliu","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf129_bb0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<318::AID-CNCR11>3.0.CO;2-6","article-title":"UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced non-small-cell lung carcinoma: a multi-institutional phase II trial. The Japan UFT Lung Cancer Study Group","volume":"88","author":"Ichinose","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf129_bb0095","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1200\/JCO.1998.16.8.2877","article-title":"Uracil\u2013tegafur in gastric carcinoma: a comprehensive review","volume":"16","author":"Takiuchi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdf129_bb0100","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0385-8146(85)80070-5","article-title":"Clinical trials on UFT in the treatment of head and neck cancer","volume":"12","author":"Tanaka","year":"1985","journal-title":"Auris Nasus Larynx"},{"key":"10.1093\/annonc\/mdf129_bb0105","first-page":"55","article-title":"Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas","volume":"5","author":"Ajani","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf129_bb0110","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<724::AID-CNCR9>3.0.CO;2-D","article-title":"Phase II study of patients with metastatic non-small-cell carcinoma of the lung treated with paclitaxel by 3-hour infusion","volume":"79","author":"Tester","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf129_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s003450050044","article-title":"Recent strategies for the use of paclitaxel in the treatment of urological malignancies","volume":"16","author":"Bokemeyer","year":"1998","journal-title":"World J Urol"},{"key":"10.1093\/annonc\/mdf129_bb0120","first-page":"91","article-title":"Paclitaxel via 1-hour infusion: clinical experience","volume":"23","author":"Greco","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf129_bb0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1997.15.1.187","article-title":"Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer","volume":"15","author":"Fennelly","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf129_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/07357909809050028","article-title":"Phase I trial of uracil\u2013tegafur (UFT) plus oral leucovorin: 28-day schedule","volume":"16","author":"Pazdur","year":"1998","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdf129_bb0135","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1200\/JCO.1999.17.6.1915","article-title":"Phase I and pharmacokinetic study on the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies","volume":"17","author":"Villalona-Calero","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419628899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/5\/755\/530836\/mdf129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:31:30Z","timestamp":1582165890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419628899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S0923753419628899"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf129","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}